Developing a new treatment for Alzheimer's disease by targeting stress response mechanisms
Official title: Lead Optimization of a Therapeutic Candidate for Alzheimer’s Disease
Funded at Stress Therapeutics, INC. · NIH-11077619 · Data updated 2026-11-12
This study is working on a new treatment for Alzheimer's disease that aims to calm down a part of the brain that gets too active and can worsen the condition, hoping to offer a safe and effective option for managing the disease over time.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stress Therapeutics, INC. NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project start | June 1, 2025 |
| Project end | May 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $349,605 |
| NIH project number | 1R43AG090243-01A1 |
| Project ID | NIH-11077619 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those experiencing symptoms related to excessive HPA axis activation.
✕Less likely to help
Patients with early-stage Alzheimer's disease or those who do not exhibit symptoms related to HPA axis dysregulation may not benefit from this research.
What this research studies
This research focuses on creating a novel treatment for Alzheimer's disease by addressing the overactivation of the hypothalamic-pituitary-adrenal (HPA) axis, which is linked to the progression of the disease. The approach involves developing a first-in-class therapeutic candidate that aims to normalize the hyperactivity of the HPA axis, which can have detrimental effects on brain function. By exploring new compounds that can effectively modulate this stress response, the research seeks to provide a long-term management solution for Alzheimer's and related conditions. Patients may benefit from a treatment that is both effective and tolerable for long-term use.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that improves the management of Alzheimer's disease and enhances the quality of life for patients.
How similar studies have gone: While there have been studies on glucocorticoid receptor antagonists and CRF1 antagonists, this approach is considered novel as it aims to develop a more effective and tolerable treatment specifically targeting HPA hyperactivity in Alzheimer's disease.
Where this research is happening
-
Stress Therapeutics, INC.
San Diego, United States Active
Researchers
- Principal investigator: Lloyd, Linda S — Stress Therapeutics, INC.
- Study coordinator: Lloyd, Linda S
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.